GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » Peter Lynch Fair Value

Invictus MD Strategies (Invictus MD Strategies) Peter Lynch Fair Value : N/A (As of May. 11, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Invictus MD Strategies's Peter Lynch Fair Value or its related term are showing as below:



IVITF's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.43
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Invictus MD Strategies Peter Lynch Fair Value Historical Data

The historical data trend for Invictus MD Strategies's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies Peter Lynch Fair Value Chart

Invictus MD Strategies Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19
Peter Lynch Fair Value
- - - - -

Invictus MD Strategies Quarterly Data
Jan15 Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Invictus MD Strategies's Peter Lynch Fair Value

For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invictus MD Strategies's Price-to-Peter-Lynch-Fair-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Invictus MD Strategies's Price-to-Peter-Lynch-Fair-Value falls into.



Invictus MD Strategies Peter Lynch Fair Value Calculation

Invictus MD Strategies's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.222
=N/A

Invictus MD Strategies's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-0.22.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Invictus MD Strategies  (OTCPK:IVITF) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Invictus MD Strategies's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.0001/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invictus MD Strategies Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Invictus MD Strategies (Invictus MD Strategies) Business Description

Traded in Other Exchanges
N/A
Address
595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.

Invictus MD Strategies (Invictus MD Strategies) Headlines

From GuruFocus

INVICTUS ANNOUNCES CHANGE TO BOARD

By Marketwired Marketwired 12-14-2019

UPDATE ON ACREAGE PHARMS LTD.

By Marketwired Marketwired 06-12-2019

ACREAGE PHARMS LTD. GRANTED OIL SALES LICENSE

By Marketwired Marketwired 08-14-2019

INVICTUS ANNOUNCES CHANGE TO BOARD

By GlobeNewswire GlobeNewswire 12-13-2019

INVICTUS ANNOUNCES $5,700,000 CONVERTIBLE DEBENTURE FINANCING

By Marketwired Marketwired 12-16-2019